Stroke forum - dedicated to improving stroke therapy
Welcome to the Boehringer Ingelheim Corporate stroke website.
The site has been recently updated with an extensive amount of up-to-date information and services on stroke. Boehringer Ingelheim aims to improve the lives of stroke patients through its products and services. Our expertise lies in acute treatment and secondary prevention of stroke.
baseline data
With 20,332 enrolled patients, PRoFESS® is the largest secondary stroke prevention trial ever conducted. It involves patients from 695 sites throughout Asia, Australia, Europe, North and South America and South Africa. The baseline characteristics of the study population have now been analysed. Read the most important facts here
News from the 16th European Stroke Conference, Glasgow The European Stroke Congress is one of the most important international medical congresses and a “highlight” in the world of neurology. This year’s ESC was held in Glasgow.
The main topics were “pathways to better stroke treatment”, “headache and stroke”, “ICH and acute management”, “small vessel disease”, and “new approaches to enhancing stroke recovery”. More than 2500 participants from 81 countries benefited from an outstanding agenda.
More information about some particularly interesting lectures can be found in the congress summary.
Results of SITS-MOST
The SITS-MOST trial was designed to determine whether treatment with intravenous alteplase within 3 hours of onset of ischaemic stroke was as safe and effective in routine clinical practice as in clinical trials. Furthermore the trial compared centres with experience in the use of thrombolysis for acute ischaemic stroke with those that were inexperienced. In January 2007, the results of SITS-MOST were published. Read a detailed summary of the results.
New: SITS-MOST slide kit
The SITS-MOST slide kit is a
PowerPoint presentation on the world’s
largest stroke registry, which was
designed to determine whether the
routine use of intravenous alteplase
within 3 hours of onset of ischaemic
stroke was as safe and effective as
reported in randomised controlled trials.
It contains the objective and rationale of the SITS-MOST trial, details of the trial design, baseline data and important results. A full list of references, as well as the prescribing information for Actilyse® can also be found within.
The SITS-MOST slide kit is now available for download. Please click here to obtain your own personal copy of the slide kit.
